The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksFrontier Ip Regulatory News (FIPP)

Share Price Information for Frontier Ip (FIPP)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 41.00
Bid: 40.00
Ask: 42.00
Change: -1.00 (-2.38%)
Spread: 2.00 (5.00%)
Open: 42.00
High: 42.00
Low: 41.00
Prev. Close: 42.00
FIPP Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Alusid - appoints David Taylor CBE to the Board

16 Mar 2021 07:00

RNS Number : 3296S
Frontier IP Group plc
16 March 2021
 

Reach - a non-regulatory announcement

AIM: FIPP

16 March 2021

 

Frontier IP Group Plc

("Frontier IP" or the "Group")

 

 

Portfolio news - Founding chief executive of English Partnerships and Amec Developments, University Pro Chancellor joins Alusid Board of Directors

 

Frontier IP, a specialist in commercialising intellectual property, notes today's announcement from portfolio company Alusid (the "Company") that David Taylor CBE has been appointed to the Board of Directors as the representative of the University of Central Lancashire ("UCLan" or the "University").

 

David is UCLan's Pro Chancellor and Chairman of the University Board, the University's governing body. He has more than 30 years' experience in the private, public and voluntary sectors, encapsulating large-scale urban regeneration projects, start-up companies and green technologies.

 

His roles have included being the founding chief executive of both English Partnerships and Amec Developments, a director of the Olympic Development Authority, and Chairman of HullCityBuild and Elevate East Lancashire. He is currently Chairman of David Taylor Partnerships, a privately-owned corporate and property company.

 

Alusid, a spin out from UCLan, creates premium-quality tiles and other architectural surfaces from recycled industrial waste ceramics, glass and other materials. Its partners include Parkside Architectural Tiles, the commercial arm of Topps Tiles, and Panaz Limited. The company is now scaling up its technology for mass manufacture, transforming production from 4,000m2 a year to 30,000m2 a month.

 

Frontier IP Chief Executive Neil Crabb said: "David's vast experience and contacts in the property sector and his strong interest in green technologies will prove invaluable as Alusid develops. We are delighted he is joining the Board."

 

 

Property entrepreneur and University of Central Lancashire Pro Chancellor David Taylor joins Alusid Board of Directors

 

Alusid is delighted to welcome David Taylor CBE to the Board of Directors as the representative of the University of Central Lancashire (UCLan).

David was appointed Pro Chancellor and Chairman of the University Board, UCLan's governing body, in 2014. He has extensive experience in the private, public and voluntary sectors. In a career spanning more than 30 years, David has built a portfolio of companies focused on the built environment and green technologies including Allied Lighting Limited, Standard Gas Technologies, Carbon Numbers Limited and Endo Enterprises (UK) Limited.

He is Chairman of David Taylor Partnerships (DTP), a Preston-based privately owned corporate and property company specialising in start-up companies and large-scale urban regeneration. Projects include a joint venture with British Land to build 980 homes, a library and a civic centre on derelict land in Canada Quays, London.

In his work for UCLan, David initiated a new £200m masterplan transforming the university presence in Preston with two new buildings, the Engineering and Innovation Centre and the Student Centre and also the University Square, the first major civic square to be developed in the North West in recent times.

His other roles include founding Chief Executive of both English Partnerships and Amec Developments, and Deputy Chairman of Preston North End Football Club, a post he has held for 25 years. He has been Chairman of HullCityBuild and Elevate East Lancashire. He was a director of the Olympic Development Authority, which organised the London 2012 games. David is interim Chairman of the Lancashire Enterprise Partnership (LEP) and has been instrumental in the LEP's development of a new strategic framework, the establishment of business-led sector groups and delivering investment for growth, through projects such as the Advanced Manufacturing Research Centre at Samlesbury Enterprise Zone, as well as securing a further £34.1m from the Government's Getting Building Fund.

He joins Alusid at an important stage in its development. The company has proved its technology to recycle industrial waste ceramics, glass and glaze into premium-quality tiles and other surfaces that can be scaled up to mass manufacture and discussions are now taking place with potential industry partners.

David was awarded a CBE for services to the community of Lancashire in 2007 and became Deputy Lieutenant of Lancashire in 2014.

Alusid is a spin out from the University of Central Lancashire. It was co-founded by Dr David Binns, Professor of Contemporary Ceramics, who is the company's Creative Director, and Dr Alasdair Bremner, a former Postdoctoral Research Fellow, who is now full time Alusid Chief Executive Officer.

 

David Taylor, Pro Chancellor and Chairman of the University Board, University of Central Lancashire, said: "I am delighted to be joining the board of Alusid as the University's representative. I am particularly pleased to be joining a company with the potential to transform tile production through its innovative green technology."

Alusid Chief Executive Officer Alasdair Bremner said: "We are very happy David is joining the board. His unparalleled experience in business and focus on green technologies will prove invaluable at this crucial stage in our development and for helping us achieve our ambitions for the business."

 

 

 

 

ENQUIRIES

 

 

Frontier IP Group Plc

T: 020 7332 2338

Neil Crabb, Chief Executive

Andrew Johnson, Communications & Investor Relations

Company website: www.frontierip.co.uk

neil@frontierip.co.uk

M: 07464 546 025

Allenby Capital Limited (Nominated Adviser)

Nick Athanas / George Payne

 

T: 0203 328 5656

 

 

 

 

ABOUT ALUSID

Alusid creates beautiful, premium-quality tiles and architectural surfaces The company creates beautiful, premium quality tiles and architectural surfaces by recycling industrial waste ceramics, glass and other materials much of which would otherwise end in landfill. Tiles are made from a minimum of 95 per cent recycled content and usually contain more.

 

The company's Sequel ranges are distributed exclusively by Parkside Architectural Tiles, the commercial arm of Topps Tiles. Sequel Vibe was named Wall Tile Of The Year in The Tile Association's prestigious awards last year.

 

Alusid also makes its own products under the brand name SilicaStone distributed in the UK by Panaz. Customers include COS, part of H&M, Christian Dior, Nando's, Harrods, Selfridges, Amazon UK and Pret-a-Manger.

 

ABout frontier IP

Frontier IP unites science and commerce by identifying strong intellectual property and accelerating its development through a range of commercialisation services. A critical part of the Group's work is involving relevant industry partners at an early stage of development to ensure technology meets real world demands and needs.

The Group looks to build and grow a portfolio of equity stakes and licence income by taking an active involvement in spin-out companies, including support for fund raising and collaboration with relevant industry partners at an early stage of development.

 

About Reach announcements

This is a Reach announcement. Reach is an investor communication service aimed at assisting listed and unlisted (including AIM quoted) companies to distribute media only / non-regulatory news releases into the public domain. Information required to be notified under the AIM Rules for Companies, Market Abuse Regulation or other regulation would be disseminated as an RNS regulatory announcement and not on Reach.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NRAFLFSAVLIELIL
Date   Source Headline
2nd May 20247:00 amRNSFrontier IP announces stake in DiaGen
17th Apr 20241:59 pmRNSHolding(s) in Company
12th Apr 20247:00 amRNSAppointment of Chief Financial Officer
2nd Apr 202412:44 pmRNSHolding(s) in Company
14th Mar 20247:00 amRNSUnaudited Half Year Results
4th Mar 20241:40 pmRNSHolding(s) in Company
29th Feb 20243:12 pmRNSSale of shares in Exscientia
30th Jan 202411:45 amRNSHolding(s) in Company
22nd Jan 20247:00 amRNSOctopus invest in Alusid as part of equity funding
29th Dec 202312:00 pmRNSTotal Voting Rights
19th Dec 20234:46 pmRNSHolding(s) in Company
15th Dec 20236:12 pmRNSReplacement - Result of AGM and Directorate Change
15th Dec 20232:07 pmRNSResult of AGM and Directorate Change
13th Dec 20237:00 amRNSPortfolio news - The Vaccine Group
11th Dec 20237:00 amRNSHolding(s) in Company
30th Nov 20235:00 pmRNSTotal Voting Rights
30th Nov 20237:00 amRNSExercise of Options & Director/PDMR Shareholdings
28th Nov 20237:00 amRNSBoard Change
21st Nov 20237:00 amRNSPosting of Annual Report and Notice of AGM
9th Nov 20235:27 pmRNSHolding(s) in Company
3rd Nov 20237:05 amRNSGrant of options
1st Nov 20235:48 pmRNSExercise of Options & PDMR Shareholdings & TVR
31st Oct 20237:01 amRNSBoard changes
31st Oct 20237:00 amRNSFinal results for the year ended 30 June 2023
23rd Oct 20237:00 amRNSNew portfolio company Deakin Bio-Hybrid Materials
12th Oct 20232:05 pmRNSHolding(s) in Company
21st Sep 20237:00 amRNSExscientia announces collaboration with Merck
14th Sep 20235:21 pmRNSHolding(s) in Company
14th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
11th Sep 20237:00 amRNSPortfolio news – Pulsiv appoints Chairman and CPO
8th Sep 20237:00 amRNSExercise of Options & Total Voting Rights
10th Aug 20238:45 amRNSPortfolio news – Fieldwork Robotics
24th Jul 20237:00 amRNSPortfolio news – CamGraPhIC loan facility
20th Jul 20235:18 pmRNSHolding(s) in Company
1st Jun 20237:00 amRNSSale of shares in Exscientia
26th May 20236:06 pmRNSHolding(s) in Company
9th May 20237:00 amRNSTopps Tiles launches first Alusid made tile range
21st Apr 20234:00 pmRNSDirectorate Change
20th Apr 20235:26 pmRNSHolding(s) in Company
27th Mar 20235:17 pmRNSHolding(s) in Company
17th Mar 20232:46 pmRNSGrant of options
15th Mar 20237:00 amRNSBoard changes
15th Mar 20237:00 amRNSUnaudited Half Year Results
30th Jan 20237:00 amRNSAlusid in collaboration with Imerys
9th Jan 20237:00 amRNSCelerum appoints David Gladding as CEO
9th Dec 20224:08 pmRNSResult of AGM
7th Dec 20221:25 pmEQSThe Vaccine Group completes two deadly disease vaccination projects
6th Dec 20227:00 amRNSFrontier IP to host Portfolio Demo Day
5th Dec 20227:00 amRNSThe Vaccine Group completes Lassa fever project
2nd Dec 20227:00 amRNSThe Vaccine Group completes vaccine project

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.